Optical coherence tomography-based measurement of drusen load predicts development of advanced age-related macular degeneration

American Journal of Ophthalmology

Volumn 158, Issue 4, 2014, Pages 757-761.e1

  Nathoo, Nawaaz A ^a   Or, Chris ^a   Young, Mei ^a   Chui, Lica ^a   Fallah, Nader ^a   Kirker, Andrew W ^a   Albiani, David A ^a   Merkur, Andrew B ^a   Forooghian, Farzin ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b RICK HANSEN INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; COHORT ANALYSIS; DRUSEN; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; ATROPHY; DISEASE COURSE; EXUDATIVE MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; METHODOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; VERY ELDERLY;

AGED, 80 AND OVER; ATROPHY; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GEOGRAPHIC ATROPHY; HUMANS; MALE; RETINAL DRUSEN; RETINAL PIGMENT EPITHELIUM; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; WET MACULAR DEGENERATION;

EID: 84908508087     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2014.06.021     Document Type: Article

References (31)

1. Velez-Montoya R, Oliver SC, Olson JL, et al. Current knowledge and trends in age-related macular degeneration: Today's and future treatments. Retina 2013;33(8):1487-1502.
2. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neo vascular agerelated macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65.e5.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-1431.
4. Complications of Age-related Macular Degeneration Prevention Trial Research Group. Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial. Ophthalmology 2008;115(9):1474-1479. 1479.e1-6.
5. Joachim N, Mitchell P, Kifley A, et al. Incidence and progression of geographic atrophy: observations from a population based cohort. Ophthalmology 2013;120(10):2042-2050.
6. Seddon JM, Reynolds R, Yu Y, et al. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 2011;118(11):2203-2211.
7. Klein R, Klein BE, Knudtson MD, et al. Fifteen-year cumulative incidence of age-related macular degeneration: The Beaver Dam Eye Study. Ophthalmology 2007;114(2):253-262.
8. Cukras C, Agron E, Klein ML, et al. Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-Related Eye Disease Study Report No. 28. Ophthalmology 2010;117(3):489-499.
9. Brader HS, Ying GS, Martin ER, et al. Characteristics of incident geographic atrophy in the complications of age-related macular degeneration prevention trial. Ophthalmology 2013; 120(9):1871-1879.
10. Sepp T, Khan JC, Thurlby DA, et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci 2006;47(2):536-540.
11. Allikmets R, Shroyer NF, Singh N, et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science 1997;277(5333):1805-1807.
12. Yang Z, Stratton C, Francis PJ, et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med 2008;359(14):1456-1463.
13. Friberg TR, Bilonick RA, Brennen P. Is drusen area really so important? An assessment of risk of conversion to neo vascular AMD based on computerized measurements of drusen. Invest Ophthalmol Vis Sci 2012;53(4): 1742-1751.
14. Silva R, Cachulo ML, Fonseca P, et al. Age-related macular degeneration and risk factors for the development of choroidal neo vascularisation in the fellow eye: A 3-year follow-up study. Ophthalmologica 2011;226(3):110-118.
15. Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006;314(5801):989-992.
16. Magnusson KP, Duan S, Sigurdsson H, et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 2006;3(1):e5.
17. Smith RT, Chan JK, Busuoic M, et al. Auto fluorescence characteristics of early, atrophic, and high-risk fellow eyes in agerelated macular degeneration. Invest Ophthalmol Vis Sci 2006; 47(12):5495-5504.
18. Yehoshua Z, Gregori G, Sadda SR, et al. Comparison of drusen area detected by spectral domain optical coherence tomography and color fundus imaging. Invest Ophthalmol Vis Sci 2013;54(4):2429-2434.
19. Yehoshua Z, Wang F, Rosenfeld PJ, et al. Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. Ophthalmology 2011;118(12):2434-2441.
20. Yehoshua Z, Rosenfeld PJ, Gregori G, et al. Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. Ophthalmology 2011;118(4):679-686.
21. Chiu SJ, Izatt JA, O'Connell RV, et al. Validated automatic segmentation of AMD pathology including drusen and geographic atrophy in SD-OCT images. Invest Ophthalmol Vis Sci 2012;53(1):53-61.
22. Jain N, Farsiu S, Khanifar AA, et al. Quantitative comparison of drusen segmented on SD-OCT versus drusen delineated on color fundus photographs. Invest Ophthalmol Vis Sci 2010; 51(10):4875-4883.
23. Vinding T, Appleyard M, Nyboe J, Jensen G. Risk factor analysis for atrophic and exudative age-related macular degeneration. An epidemiological study of 1000 aged individuals. Acta Ophthalmol (Copenh) 1992;70(1):66-72.
24. Chew EY, Clemons TE, Agron E, et al. Ten-year follow-up of age-related macular degeneration in the Age-Related Eye Disease Study: AREDS Report No. 36. JAMA Ophthalmol 2014;132(3):272-277.
25. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the retinal pigment epithelium. Eye (Lond) 1988;2(Pt 5):552-577.
26. Sunness JS, Gonzalez-Baron J, Applegate CA, et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology 1999;106(9):1768-1779.
27. Williams MA, Craig D, Passmore P, Silvestri G. Retinal drusen: harbingers of age, safe havens for trouble. Age Ageing 2009;38(6):648-654.
28. Buschini E, Piras A, Nuzzi R, Vercelli A. Age related macular degeneration and drusen: neuro inflammation in the retina. Prog Neurobiol 2011;95(1):14-25.
29. Murakami Y, Matsumoto H, Roh M, et al. Programmed necrosis, not apoptosis, is a key mediator of cell loss and DAMP-mediated inflammation in dsRNA-induced retinal degeneration. Cell Death Differ 2014;21(2):270-277.
30. Ouyang Y, Heussen FM, Hariri A, et al. Optical coherence tomography-based observation of the natural history of drusenoid lesion in eyes with dry age-related macular degeneration. Ophthalmology 2013;120(12):2656-2665.
31. Sayanagi K, Sharma S, Yamamoto T, Kaiser PK. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology 2009;116(5):947-955.